| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5882974 | Clinical Lymphoma Myeloma and Leukemia | 2014 | 7 Pages |
Abstract
A substantial percentage of apparently transplant-eligible patients with newly diagnosed MM do not proceed to upfront ASCT. Community practice appears to diverge from clinical guidelines. The reasons for this divergence require further study but reasons may include perceptions of toxicity vs. benefits of upfront ASCT.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Nicole Wong Doo, Michael Coory, Victoria White, Simon J. Harrison, H. Miles Prince, Jeremy L. Millar, Margaret Dimech, Graham G. Giles, IMPROVE Project IMPROVE Project,